FDA Risk Communication Advisory Committee
Location: 5630 Fishers Lane, Room 1066, Rockville, MD
August 14-15, 2008

Topics for Committee Discussion

- In light of information presented by the RCAC members and the FDA panelists, please discuss what scientifically supportable, empirically-based, steps FDA should take to improve the effectiveness of communications.

- As noted in the FDA presentations, FDA's communications may be drafted for a range of objectives and for a range of audiences. Please discuss how the success of a communication may be evaluated for different objectives.

- FDA has adopted, especially in regard to drug products, a policy of increased transparency about early or emerging (possibly still uncertain) risk information. From the perspective of your communities and experience, what might be the effects of this policy? How might the FDA learn more about such effects, if necessary?

- FDA uses certain terms that have special regulatory meaning and importance (example: product X has been shown ***safe and effective*** for its intended use). From the perspective of your communities and experience, what might be conveyed by such terms? How might the FDA learn more about such key terms, if necessary?